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MONOCLONAL ANTIBODIES IN THE
STUDY OF TUMOUR ANTIGENS. H.
KOPROWSKI, The Wistar Institute, Phila-
delphia, PA 19104, U.S.A.
Monoclonal antibodies (MA) were produced
by hybridomas obtained through the fusion
of mouse myeloma cells with lymphocytes
obtained from the spleens of mice or rats
immunized against a variety of human
tumour antigens. Of the 11 MA that bind in
radioimmunoassay (RIA) to human melan-
oma, 3 recognize the DR antigen, which is
also expressed by human lymphocytes, 1
recognizes an antigen that is also expressed by
some astrocytomas but not by any other
cells and 6 define antigens expressed only by
melanomas; 7 of these immunoprecipitate
antigens of different mol. wts. Of 11 MA that
bind to colorectal carcinoma (CRC), 1 defines
carcinoembryonic antigen (180,000 mol. wt),
3 bind to a monosialoganglioside that can be
isolated from CRC and meconium but not
from other tissue, 3 react with neutral glyco-
lipids extracted from CRC, and 2 immuno-
precipitate a CRC antigen with mol. wt
21-28,000; 1 of these MA effectively sup-
presses the growth of CRC in nude mice. MA
have also been raised through the immuniza-
tion of animals with cells from astrocytoma,
lung adenocarcinoma, lung oat-cell carcinoma
and breast carcinoma; identification of the
antigens recognized by these MA is still in
pr-elimninary stages.
TWO ANTIGENS IDENTIFIED ON
HUMAN MELANOMA CELLS BY
MONOCLONAL ANTIBODIES: K. E.
HELLSTROM, I. HELLSTROM, J. P. BROWN,
M-Y. YEH, R. G. WOODBURY & K. NIsHI-
YAMA, Fred Hutchinson Cancer Research
Center, Seattle, Washington, U.S.A.
We have immunized BALB/c mice with
cultivated human melanoma cells and hybrid-
ized spleen cells from the immunized mice
with NS-1 or Sp-2/0-Agl4 myeloma cells.
The hybridomas have been screened by bind-
ing assays, and antibody specificities tested
on a large panel of cells, including the im-
munizing melanoma, other melanomas, non-
melanoma tumours of different types, B and
T cell lines, and normal cells. Two antigens
defined have been of particular interest. The
first, Ag3.1, is expressed less by the melan-
oma, M1804, used for immunization, but can
be detected in smaller amounts also on some
other melanomas. An JgG2a antibody to 3.1
gives complement-dependent cytotoxicity as
well as ADCC in the presence of human
leucocytes. The antigen is expressed in
tumour biopsy material. Antigen-negative
variants can be selected from tumours ex-
pressing Ag3.1 and from Ag3.1l+ clones
established from such tumours. The molecu-
lar nature ofAg3.1 is unknown; it is possibly
a glycolipid.
The second, Agp97, is a glycoprotein of
mnol. wt 97,000 on SDS-PAGE. By using
monoclonal antibodies to different antigenic
determinant on the p97 molecule, a very
sensitive "double determinant imnmuno-
assay" was developed, which was used to
extensively analyse for Agp97 in various cells
obtained from cultures, as well as from
tumour and tissue biopsies. Using such assays
we found that Agp97 is present on most
tumours and, in small amounts, in most
normal tissues, but certain melanomas have
about 100 times more Agp97 than normal
cells we have tested.
PREPARATION OF MONOCLONAL
ANTIBODIES AGAINST MYCO-
PLASMA. C. VENNEG000* A. POLAKt &
A. JONKER*, *Netherlands Cancer Institute,
Amsterdam, and tNational Institute of Public
Health, Bilthoven, The Netherlands
Monoclonal antibodies wtere prepared against
the human melanoma cell line SK-Mel-25.
One million living SK-Mel-25 cells were in-
jected into BALB/c mice i.p and s.c. Booster
injections with 106 living cells were given i.v.
on Days 7, 14 and 35. Spleein cells were
harvested 4 days after the last booster in-
jection and fused with the myeloma cell line
P3x 63 Ag8. The presence of anti-SK-Mel-25
antibodies in the supernatants was tested
with 1251-F(ab')2 anti-mouse IgG and IgM.
Test/control ratios >2 wiere considered posi-
tive. One of the hybridomas wi-as selected for
subsequent cloning and search for specificity
for melanoma. Positive reactions were found
on a number of melanoma cell lines, but also
on various control cell lines. In immuno-
fluorescence tests patchy structures were
visible that seemed to be attached very
loosely to the cell surface. Closer examination
gave indications that the monoclonal anti-
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bodies were directed against a mycoplasma
that had infected the cell lines. There is now
evidence that the monoclonal antibodies are
directed against Mycoplasma hyorhinis.
These results demonstrate the necessity of
thorough control on mycoplasma infections
in cells used for preparation of monoclonal
antibodies, since the SK-Mel-25 cells had
been cultured in the presence ofthe antibiotic
kanamycin, grew fast, and did not contain
readily detectable mycoplasma infection when
usedfor immunization.
CELL-SURFACE ANTIGENS OF HU-
MAN MALIGNANT MELANOMAS DE-
FINED BY MONOCLONAL ANTI-
BODIES: W. G. DIPPOLD, K. 0. LLOYD, L.
Li, H. IKEDA, H. F. OETTGEN & L. J. OLD,
Memorial Sloan-Kettering Cancer Center, New
York, NY 10021
Eighteen mouse monoclonal antibodies were
selected for reactivity with cell-surface anti-
gens ofthe immunizing human melanoma cell
line, SK-MEL-28. Six distinct antigenic
systems were defined by direct serological
assays and absorption tests, using a panel of
41 cell lines derived from normal and malig-
nant human tissues. Biochemical analysis
indicated that 2 of the antigens are glyco-
proteins with mol. wts of 95,000 and 150,000
(gp95 and gp150). Two other antigenic sys-
tems (05 and R24 group) are associated with
heat-stable molecules with the characteristics
of glycoplipids. The remaining two antigens
(Ml9 and R8) are heat labile, but molecular
characterization has not been possible. Each
of the antigenic systems has a distinctive
pattern of distribution on various cell types,
varying from a broad representation to more
restricted occurrence. 05 appears to be a
species antigen, being present on virtually
every human cell type tested. gp95, gpl50,
M19 and R8 are found on a characteristic pro-
portion of melanomas, astrocytomas and
epithelial cancers, as well as on normal kidney
cells. The antigen defined by the R24 antibody
has the most restricted distribution of all;
highest reactivity is found with melanomas
and astrocytomas, whereas epithelial cell
types, fibroblasts and cells of haemopoietic
origin lack R24. Although occurrence ofgp95,
gpl50, Ml9 and Ps distinguishes a small sub-
set of melanomas not expressing these anti-
gens, R24 is found on all melanoma cells.
HUMAN MELANOMA-ASSOCIATED
ANTIGEN(S) DETECTED BY MONO-
CLONAL ANTIBODIES. S. CARREL, J.-P.
MACH & R. S. ACCOLLA, UnitofHuman Cancer
Immunology, Lausanne Branch, Ludwig Insti-
tute for Cancer Research, 1066 Epalinges,
Switzerland
Hybridomas were derived from 5 fusions
between mouse myeloma cells P3-NSI/lAg4
or P3x63/Ag8 and spleen cells from mice
immunized with membranes from 2 human
melanoma cell lines Me43 and IGR-3. Of 193
hybrids obtained, 55 secreted antibodies that
reacted with the melanoma cell lines used for
immunization, as assayed by an indirect
antibody-binding radioimmunoassay. After a
first screening for the absence ofreactivity on
2 non-melanoma control cell lines, a total of
9 hybrids, 3 from the first, 2 from the third,
3 from the fourth and 1 from the fifth fusion
were selected and cloned by limiting dilution.
The specificity of these monoclonal anti-
bodies was then investigated with the same
binding assay on a panel of cell lines derived
from melanomas, non-melanoma tumours and
normal peripheral-blood lymphocytes, nor-
mal skin fibroblasts and normal spermatozoa.
After this specificity analysis, the 9 selected
hybridoma products could be classified into
3 groups, antibodies binding to melanomas
only, antibodies binding to melanomas and
glioblastomas, and antibodies directed against
HLA-DR antigens. By complement-depend-
ent cytotoxicity experiments using 51Cr-
labelled target cells, it was shown that anti-
bodies from 3 clones were able to lyse melan-
omatarget cells. Reciprocalbindinginhibition
tests using 3H-leucine-labelled antibodies
showed that 3 hybridoma products cross-
reacting with glioblastomas were directed
against different antigenic determinants
located on separated molecules.
BIOCHEMICAL ANALYSIS OF MEL-
ANOMA-ASSOCIATED ANTIGENS
DEFINED BY MONOCLONAL ANTI-
BODIES: J. JOHNSON, G. RIETHMULLER &
T. MEO, Institutfir Immunologie der Universi-
tat Miunchen, Miinchen, W. Germany
Monoclonal antibodies were produced by
immunizing mice with melanoma cell lines
derived from living patients. Based on their
reactivity with a cell panel consisting of cell
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lines of different tissue origin, the antibodies
obtained were used to define 4 broad classes
of melanoma-associated antigens. Sepharose-
coupled monoclonal antibodies were used to
isolate selected antigens from cell lysates of
biosynthetically or surface-labelled cells and
the antigens were analysed by SDS poly-
acrylamide gel electrophoresis and auto-
radiography.
Two antigens which are found on most
tested melanoma and carcinoma cell lines but
are absent from lymphoid lines have been
analysed in detail. Antibody 15.75 precipi-
tates a glycoprotein of 74 kilodaltons (kd)
from the surface of both melanoma and
carcinoma cell lines. A surface glycoprotein of
49 kd is precipitated by antibody 15.95 from
melanoma and carcinoma cell lines. Both
antigens can be biosynthetically labelled with
35S-methionine. GP49 is present on a terato-
carcinoma cell line, and also on 3 foetal fibro-
blast lines which have been tested. Antibody
16.23 recognizes an antigen which was found
only on the immunizing melanoma and on a
lymphoblastoid cell line derived from the
tumour donor. From the melanoma, this
antibody precipitates 3 polypeptides of mol.
wt 28, 31 and 38 kd. The antigen defined by
antibody 16.54 is found on lymphoblastoid
cell lines as well as on melanomas, though it is
not detected in PBL or fibroblasts. From the
surface of melanoma cells, this antibody pre-
cipitates 2 polypeptide chains of 95 and 18
kd. The genetic control of expression of these
antigens is currently under investigation,
using a series of interspecific somatic-cell
hybrids containing various human chromo-
somes.
MONOCLONAL ANTI-CEA ANTI-
BODIES: G. T. ROGERS, G. A. RAWLINS &
K. D. BAGSHAWE, Department of Medical
Oncology, Charing Cross Hospital, London,
W.6
Somatic-cell hybridization and clonal-selec-
tion experiments have been used to produce
2 distinct monoclonal antisera against CEA.
MS/i which binds a maximum of 270% of
radiolabelled CEA can be used at a dilution
of 1: 1000 for double-antibody RIA. Competi-
tive binding with MS/i has shown that 8600
ng/ml of unlabelled CEA extracted from
tumour is required to produce 500",, 'dis-
placement" of bound label. In contrast, only
30 ng/ml of CEA extracted from patients'
sera is required to produce this displacement.
ClinicalRIAusingMS/I hasshow vnMS/I-bind-
ing CEA to be associated writh many forms of
cancer, although its expression in the serum
often differs from that of conventional CEA.
The other monoclonal antibody, MA/200,
is able to bind CEA more readily, with a
maximum binding of 510% of 1 ng of [1251]-
CEA. Optimal double-antibody RIA condi-
tions, obtained using MA/200 at a dilution
of 1:20,000, produced 16% binding of
radiolabelled CEA. Competitive-inhibition
experiments with MA/200 have shown that,
unlike MS/1, only 80 ng/ml of unlabelled
tumour CEA is required to produce 5000 dis-
placement of bound label. Clinical RIA data
obtained with MS/I and MA/200 are being
evaluated.
ANTI-COLON-CARCINOMA ANTI-
BODIES ANALYSED WITH IMMUNO-
FLUORESCENCE IN FROZEN SEC-
TIONS: J. BERRY, F. TAKEI & E. LENNOX,
MRC Laboratory of Molecular Biology, Hills
Road, Cambridge
Fourteen rat monoclonal antibodies raised
against membranes from human colonic
adenocarcinoma, showing in vitro binding to
membranes, were assessed by indirect im-
munofluorescence on cryostat sections of
fresh human tissue.
Seven supernates showed strong specific
fluorescence against such components of
normal human colonic mucosa as smooth
muscle, goblet-cell mucin and epithelium.
There were several different patterns of
epithelial fluorescence, which depended on
the antibody and the site from which the
sample of mucosa was taken. None of the
antibodies gave the same pattern, whilst all
were consistent.
Activity on the corresponding colonic
carcinoma was generally less than that on
normal mucosa, or absent. One supernate
showed enhanced antitumour activity and
was also active against a crude extract of
CEA. No supernate gave fluorescence with
tumour and was inactive on normal colon.
Immunofluorescence and other histochemi-
cal techniques a,re available for separating
different antibody activites again,st complex
tissue antigens, and w%ill help define the
possible application of these antibodies.
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MONOCLONAL ANTIBODIES TO
HUMAN CARCINOMA CELL LINES:
J. ARKLIE & W. F. BODMER, Imperial Cancer
Research Fund, London
The following monoclonal antibodies have
been raised by immunizing BALB/c mice
with whole cells of carcinoma cell lines: anti-
bodies 72B1 and AAP1 against D98/AH-2
(cervical carcinoma) and antibodies AUA1,
D20L and C15L against LoVo (colonic carci-
noma). AAPI has been characterized as
specific for the enzyme intestinal alkaline
phosphatase that is produced ectopically by
D98/AH-2. Characterization of the other
antibodies by [1251]-RAM trace binding assay
against a panel of carcinoma, fibroblast and
lymphoid cell lines, has shown that all are
epithelium-specific, butthattherearepatterns
of binding within the epithelial panel such
that 72B1 is D98/AH-2 specific, D20L reacts
with 4/14 lines, AUA1 with 13/14 lines (in-
cluding 3 colon-carcinoma lines) and C15L
with 12/14 lines. The mol. wts ofthe antigens
recognized by C15L and D20L, as revealed
by SDS-PAGE, were 60,000 and 40,000
respectively. In immunoperoxidase studies on
formalin-fixed paraffin sections of normal
tissue, D20L bound only to small intestine
whereas AUA1 bound to both small and large
intestine. Using the immunoperoxidase tech-
nique we are currently screening these mono-
clonal antibodies against a panel of tumour
types.
internally labelled with 3H-lysine, and their
antibody activity against a variety of mem-
brane preparations determined. Nine human
monoclonal antibodies were found which
bound to molecules on lung-cancer mem-
branes but not to those found in normal lung
membranes from the same patient. The deter-
minants against which these antibodies were
directed were found on lung tumours from
several different patients.
The abstract which occupied this space was
withdrawn at the last minute.
HUMAN MONOCLONAL ANTIBODIES
TO LUNG-CANCER ANTIGENS. K.
SIKORA & R. WRIGHT, MRC Clinical Oncology
and Radiotherapeutics Unit, The Medical
School, Hills Road, Cambridge
Lymphocytes obtained from hilar and bron-
chial lymph nodes from 23 patients under-
going radical surgery for carcinoma of the
bronchus were fused with established rat or
mouse myeloma lines, using polyethylene
glycol. Hybrids were obtained from 12
patients. There was no apparent correlation
between successful fusion and the age, sex or
blood group of the patient. 62% of the re-
sultant hybrids were found to be secreting
human immunoglobulin, by a sensitive pro-
tein A-coupled SRBC-lysis assay. Immuno-
globulins synthesized by such hybrids were
39
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The abstract which occupied this space was
withdrawn at the last minute.
DISTRIBUTION OF HLA CLASS 1
ANTIGENS IN NORMAL HUMAN
TISSUES AND MAMMARY CANCER.
J. O'D. MCGEE, K. A. FLEMING, A.
MCMICHAEL, J. WOODS & J. MORTON,
University of Oxford, Nuffield Departments
of Pathology and Medicine, John Radcliffe
Hospital, Oxford
HLA antigens are glycoproteins which are
presumed to be located exclusively on cell
surfaces. These antigens are of two classes:
Class 1 (HLA-A,B,C) and Class 2 (HLA-DR).
It has been assumed from absorption experi-
ments of HLA antisera with whole-tissue
homogenates that these antigens are present
in virtually all nucleated cells.
HLA antigens modulate some cell-mediated
immune responses by major histocompati-
bility complex (MHC) restriction of T-cell-
mediated immunity. This is of proven rele-
vance in immunity to viral infections, and
may also be relevant to T-cell-mediated re-
sponses to tumour cells.
In this paper, using monoclonal antibodies
it is shown that HLA Class 2 antigens are
expressed only on normal lymphoid cells,
vascular endothelial, and certain types of
epithelial cell (including mammary-duct epi-
thelium). In contrast HLA (A,B,C) antigens
are expressed in half of 19 human mammary
cancers examined to date. A prospective
study is underway to determine whether the
expression ofHLA Class 1 antigens on human
mammary cancer cells is ofprognostic signifi-
cance since the natural history of these
tumours is variable.
APPLICATION OF MONOCLONAL
ANTIBODY AGAINST A TUMOUR-
SPECIFIC ANTIGEN ON A NATUR-
ALLY ARISING RAT MAMMARY
CARCINOMA. R. W. BALDWIN, M. J.
EMBLETON, B. GUNN, J. A. JONES, J. G.
MIDDLE, M. V. PIMM & M. R. PRICE, Cancer
Research Campaign Laboratories, University
ofNottingham, Nottingham NG7 2RD
Inter-specific hybridization of spleen cells
from a WAB/Not rat immunized against
syngeneic grafts of a naturally arising mam-
mary carcinoma (Sp4) and P3-NSI-Ag4
mouse myeloma cells has been used to pro-
duce hybridomas secreting antibody which
detects a tumour-specific antigen. The
antibody secreted by one cloned cell
line (Sp4 MoAb) has been used in a
number of studies on the immunobiology of
this rat mammary carcinoma. This includes
tumour-antigen isolation using affinity
chromatography of tumour extracts on Sp4
MoAb cross-linked on Sepharose 4B. Sp4
MoAb has also been evaluated as a drug
carrierfortherapyand for tumourlocalization
using l25I-labelled antibody.
A LIBRARY OF MONOCLONAL ANTI-
BODIES AGAINST HUMAN HAEMO-
POIETIC CELLS: ANALYSIS OFANTI-
GEN EXPRESSION DURING EARLY
HAEMOPOIETIC DIFFERENTIATION
AND APPLICATION TO THE DIFFER-
ENTIAL DIAGNOSIS OF LEUKAEMIA.
M. F. GREAVES, J. ROBINSON, R. SUTHER-
LAND & R. A. NEWMAN, Membrane Immun-
ology Laboratory, Imperial Cancer Research
Fund, London, G. GOLDSTEIN & P. KUNG,
Ortho Pharmaceutical Corporation, Raritan,
New Jersey, U.S.A., P. EDWARDS, Ludwig
Institute for Cancer Research, Sutton, Surrey
& A. MCMICHAEL, Dept Surgery, Radcliffe
Infirmary, Oxford
A panel of 25 monoclonal antibodies with
selective reactivity against one or more of
each of the haemopoietic lineages (T, B
lymphoid, erythroid, granulocytic, monocytic
and platelet) in addition to a series of mono-
clonals specific for HLA-ABC, HLA-DR or
132-microglobulin, have been assessed for their
reactivity against a large series of leuk-
aemias and leukaemic cell lines. Several im-
portant new observations emerged from this
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study including the remarkable hetero-
geneity of phenotype in T-cell malignancy
(which may nevertheless parallel normal
'T-cell differentiation) and the detection of
cryptic or equivocal erythroid or megakaryo-
blastic leukaemias with anti-glycophorin or
anti-platelet antibodies respectively. Several
antibodies which were independently pro-
duced react concordantly and may bind to
the same structure; e.g. (TIOI, L17F12 and
OKT1) (OKT6 and NA134) (J-5 anti-cALL
and rabbit anti-cALL). A number of the
OKT series of anti-T monoclonals have in-
teresting features; e.g. OKT11 binds to E-
rosette receptors, and OKT9 binds to a
structure with a widespread expression on
tumour cells. The biochemical features of
some of these "leukaemia-associated" anti-
gens identified by these monoclonals have
been investigated; e.g. J-5 cALL (=gplO0),
BA-2 anti-ALL (=p26), OKT9 (=p95/100),
Ia/HLA-DR (=p28 + p3O+p33).
We are attempting to compile a pheno-
typic profile ofnormal haemopoietic differen-
tiation using these monoclonals, and have
been able to delineate a sequence of cell-
surface antigen expression during erythroid
differentiation from the BFU-E to the
mature erythrocyte, byfluorescence-activated
cell sorting. This type of analysis provides
some interesting insight into the timing of
appearance of particular structures of in-
terest; e.g. HLA-DR or BFU-E, glycophorin
on the post-CFU-E cells, Band III on
erythrocytes.
THE USE OF MONOCLONAL ANTI-
BODIES IN HISTOLOGICAL ANA-
LYSIS AND MARROW TRANSPLANT-
ATION: A REVIEW. G. JANOSSY, Depart-
ment of Immunology, Royal Free Hospital,
London, NW3
The lecture reviews three areas. First, a few
examples of markers for normal differentia-
tion antigens which can be used to find
malignant cells. A typical example is the
identification of cells expressing thymocyte
phenotype in marrow. These may correspond
to thymic ALL blasts. Similarly TdT+ cells
in the testis and the cerebrospinal fluid indi-
cate the presence of leukaemia.
Secondly, the current data on identifying
lymphocyte subpopulations by monoclonal
antibodies in tissue sections. As monoclonal
antibodies to well defined functional lymphoid
subsets exist, this technology may provide a
much needed link between classical histology
and lymphocyte functional assays carried out
in vitro. It is very likely that the analysis of
the reactivity pattern of monoclonal anti-
bodies on tissue sections will provide new
reagents against monocyte-macrophage and
B-lymphocyte subpopulations.
Thirdly, a few simple techniques standard-
ize monoclonal antibodies for marrow trans-
plantation. These include the morphological
analysis of bone marrow precursor cells (such
as TdT+ putative lymphoid precursors and
myeloblasts) and functional assays (e.g.
CFU-C test). These tests were used to
analyse a large panel ofreagents. OKT3 anti-
body, made by Ortho Laboratories, seems to
be the best candidate for attempting to re-
move T lymphocytes in order to prevent
graft-versus-host disease in allogeneic mar-
row transplantation. This antibody has
opsonizing capacity. The clinical results with
this antibody in GVH prevention (3 patients
transplanted at the Royal Free Hospital;
G. Prentice, personal communication) are
encouraging. The antibody did not have
harmful side effects, but longer follow-up and
more experience is necessary before final con-
clusions can be drawn.
MONOCLONAL ANTIBODIES TO
HUMAN CELL SURFACE ANTIGENS.
G. BROWN & I. C. M. MACLENNAN, Dept of
Immunology, University ofBirmingham, J. M.
BASTIN, Nuffield Dept of Clinical Medicine,
University of Oxford & F. M. KOURILSKY,
Centre d'Immunologie, Marseille
Mice were immunized with cells from patients
with acute myeloblastic leukaemia and
chronic lymphocytic leukaemia. These were
presented as membrane preparations, whole
cells and homogenized cells. The hybrid
clones, selected by indirect radioactive bind-
ing against the immunizing cells, produced
antibody against: (1) antigens which are
found on a wide range ofnormal cells (25/39);
(2) leucocyte-associated antigens (13/39) and
(3) a lymphoid-associated antigen (1/39).
Primary selection of hybridoma cultures was
also based on the production of mouse
immunoglobulin. Forty-seven immunoglobu-
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lin producing hybridomas were selected, of
which only 20 had activity when tested using
an indirect radioactive binding assay against
the immunizing cells. Detailed analysis of 13
of the remaining 27 has revealed antibodies
reactive against: (1) an antigen expressed in
relatively low amounts on myeloid cells;
(2) an antigen expressed on cell lines tested,
large mononuclear cells and proliferating
cells in squamous epithelium and germinal
centres; (3) a subpopulation (1-6%) of
peripheral-blood lymphocytes and (4) cyto-
plasmic components. It is concluded that
primary selection of hybridomas on the basis
of mouse immunoglobulin production is an
important adjunct to selection using surface-
binding assays against the immunizing cells.
ANTIGENS ON THE SURFACE OF
THE BURKITT LYMPHOMA LINE
DAUDI. V. VAN HEYNINGEN, K. Guy, D.
CRICHTON, M. MOXLEY & C. M. STEEL, MRC
Clinical and Population Cytogenetics Unit,
Western Royal Hospital, Edinburgh EH4 2XU
We have raised 4 B-cell-specific monoclonal
antibodies (MCAs) following immunization of
BALB/c mice with DAUDI cells. Three ofthe
MCAs, DA6-231, -164 and -147, define non-
polymorphic determinants. The fourth, DA6-
127, is directed against a polymorphic anti-
gen. Preliminary biochemical analysis sug-
gests that 231, 164 and 147 each precipitate
HLA-DR-like 33K/28K dimeric molecules.
Binding of 164 on a given cell line or on
peripheral B cells is always lower than of231.
164 partially inhibits the binding of 231,
whilst 231 completely inhibits 164. 164 has
also been found absent from a 231+ leukaemic
marrow sample. We consider that 164 defines
a subset of 231-determinant-bearing mole-
cules and mayidentify the product ofa second
DR-like locus. 147 is very weakly represented
on peripheral B lymphocytes but is strongly
present on all B lymphoblastoid lines and on
all 231+ leukaemic cells tested (including
several chronic lymphatic and a myelo-
monocytic) as well as on a B lymphoma and
an established myeloma line. 164 and 147
strongly inhibit mixed lymphocyte reactions
in the absence of complement; 231 inhibits
moderately under the same conditions.
MONOCLONAL ANTIBODIES RAISED
AGAINST HUMAN ALPHAFOETO-
PROTEIN (AFP). V. VAN HEYNINGEN*, D.
CRICHTON*, S. LAWRIE*, L. BARRONt &
D. J. H. BROCKt, *MRC Clinical and Popu-
lation Cytogenetics Unit and tDepartment of
Human Genetics, Western General Hospital,
Edinburgh EH4 2XU
Fusion of spleen cells, from BALB/c mice
immunized with purified human AFP, with
the X63NS1 myeloma line, has led to the
isolation of 5 anti-AFP monoclonal antibody
(MCA) secreting clones. Three of these have
been extensively studied. 21.1 (IgA), 21.2
(IgGj) and 22.4 (IgGj) all bind [125J]-AFP
in a polyethylene glycol (PEG) dependent
precipitation assay. However, the system is
much more sensitive to carrier-protein con-
centration than when conventional antisera
are used. Co-operativity is found when com-
binations of 2 or all 3 MCAs are used to
generate antibody dilution or radioimmuno-
assay (RIA) curves. 21.2-derived ascites fluid
alone or in combination with the other MCAs
can be used at 10-4 dilution in RIA. A solid-
phase method using Sepharose-bound second
antibody gives precipitation levels com-
parable with the PEG system. 125I-labelled
21.2 performs very well in an immunoradio-
metric assay (IRMA) with conventional sheep
anti-AFP used as the solid phase. (IRMA
work carried out by W. H. Hunter et al.,
MRC Immunoassay Team.)
MONOCLONAL ANTIBODIES TO HU-
MAN LYMPHOMA CELLS. P. BRICKELL,
I. MCCONNELL & C. MILSTEIN, MRC Centre,
Hills Road, Cambridge, CB2 2QH, England
A number of monoclonal antibodies to EBV-
transformed B cells have been raised in rats.
Some of these monoclonal antibodies were
shown to be lymphoma-cell specific, in that
they only reacted with in vitro cultured cell
lines derived from patients with Burkitt's
lymphoma. These same monoclonal anti-
bodies failed to react with EBV-transformed
lymphoblastoid cell lines and with normal
lymphocytes. The lymphoma-specific mono-
clonal antibodies did not distinguish between
EBV- and EBV+ lymphoma lines.
A monoclonal antibody to the HLA-DR
locus was also described. The determinant
recognized by this antibody is monomorphic
566WORKSHOP ON MONOCLONAL ANTIBODIES
in man but polymorphic in mic
studies with inbred recombinan
mice show that this antigen is
with H-2 haplotypes B, D and Q,
for by genes within the IA sub-
monoclonal antibody was found
tate 3 polypeptide chains frc
labelled Raji cells. These inclue
pected 34,000 dalton and 28,000 (
peptides, as well as a third co
25,000 dalton. The origin of the
peptide is not known. It may
post-translational modification
glycosylated form ofthe 28,000 d
Alternatively, this monoclonal an
be precipitating two distinct s
chain.
MONOCLONAL AUTOAN'
WITH BLOOD GROUP I AN]
FICITIES. T. FEIZI, Clinical Resi
Watford Road, Harrow, Middlese;
Among the erythrocyte autoai
chronic cold-agglutinin disease, t
are monoclonal IgM proteins dire
the blood group I and i antigens
gen is a linear and I a branched c
chain made up of N-acetyl
(Gal/l1-÷4GlcNAc) units as follov
i GalBl -+4GlcNAcf31-+3Galfl1
I
4GlcNAc/l
Gal/3l -+4GlcNAc,l
Galpl-+4GlcNAcpl
6Gal/ll 41
These structures occur on a ve
types and are carried on glycol
glycosphingolipids. They can
glycosylated and converted into
ABH-active structures and ganj
Their antigenicities are totally
masked by these additional glycc
The monoclonal anti-I and
bodies ofindividual donors recogr
oligosaccharide domains on thes
(Feizi et al. (1979) J. Exp. Med., 1
they are proving valuable reagen
of antigenic changes associated w
genesis of erythroid cells, (b) di
-e. Mapping
t strains of
s associated
and is coded
region. This
to precipi-
)m surface-
led the ex-
dalton poly-
mponent of
latter poly-
of teratocarcinomas in vitro and (c) diseases
ofthe gastric mucosa.
MONOCLONAL ANTIBODIES
AGAINST HUMAN NEUROBLAST-
OMA ANTIGENS AND HUMAN LEUK-
EMIA ANTIGENS. R. H. KENNETT, Z.
JONAK, B. HAAs & R. BYRD, Department of
Human Genetics, Univ. of Pa. School of
Medicine, Philadelphia, Pa. 19104, U.S.A.
represent a Monoclonal antibodies were made against
or a non- human neuroblastoma cells precoated with
lalton chain. an antiserum against a human lympho-
Ltibody may blastoid line. The antibody PI153/3 reacts
,pecies of with human tumours of neuroectodermal
origin and with foetal brain. The antigen is
the carbohydrate portion of a cell-surface
glycoprotein. A cross-reacting antigen is pre-
sent on B-cell and null-cell leukaemias, and
TI.BODIES on immature lymphocytes. A second anti-
DcSPECIe- body, P3B1C3, reacts with B cells and null
earchCentre, cells, and used in combination these anti-
) HA1 3UJ bodies makes it possible to identify neuro-
in blastomas in marrow, and also to identify and hetibadies i classify leukaemia cells.
the maJority We have also prepared a panel of mono-
cted against clonal antibodies against Reh, an acute
bThe
i anti- lymphoblastic leukaemia (ALL) cell line
arbohydrate derived from a patient with non-B non-T
Ilactosamine ALL. Monoclonal antibodies obtained after
vs: immunization with whole cells, KCI glyco-
protein extracts, solubilized vesicle prepara-
tions, or cell-culture supernatants, were com-
>3Galfll- pared with regard to number of positive
hybrid clones and specificity for Reh. Im-
munization with concentrated culture super-
natants produced more antibodies that, after
GlcNAc,Bl screening on 4 cell types, showed specificity
I, for Reh.
3Gal/l- A model in which monoclonal antibodies
may react with molecules on the cell surface
ariety of cell which are involved in growth control is pre-
proteins and sented. It is suggested that these antibodies
be further may mimic the effect of the normal growth-
blood-group control messenger and stimulate the Reh
gliosides. cells to stop dividing and differentiate. Four
or partially of the antibodies made against Reh have
)sylations. been shown to inhibit the uptake of [3H]-dT.
anti-i anti- Three ofthese also inhibit the proliferation of
nize different the T-cell line CCRF/CEM. The fourth does
;e structures not inhibit CCRF/CEM. It is suggested that
49, 975) and monoclonal antibodies will be useful for
its in studies identifying all surface molecules involved in
rith (a) onto- growth control and differentiation mech-
ifferentiation anisms.
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NEURAL-FIBROBLAST ANTIGEN ON
HUMAN GLIOMA, NEUROBLAST-
OMA, AND SARCOMA CELLS DE-
FINED WITH A MONOCLONAL ANTI-
BODY. R. C. SEEGER & Y. L. DANON,
Department ofPediatrics, Centerfor the Health
Sciences, UCLA School of Medicine, Los
Angeles, California 90024, U.S.A.
An antigen that is selectively expressed by
neural cells and fibroblasts, and by glioma,
neuroblastoma and sarcoma cells, was de-
fined with monoclonal antibody 390 (Ab390).
Quantitative absorption with adult tissues
followed by testing on antigen positive
LA-N-1 neuroblastoma cells, demonstrated
a large quantity of antigen associated with
brain and 90 to 10,000-fold less associated
with kidney, lung, thymus, liver, adrenal,
colon, and muscle. Among first and second
trimester foetal tissues, brain had the most
antigen, but this was significantly less than
that in adult brain. The antibody also reacted
with fibroblasts, but did not with mono-
nuclear leucocytes, thymocytes or erythro-
cytes. Of 29 cultured tumour-cell lines, bind-
ing was greatest to gliomas, moderate to
neuroblastomas, sarcomas, teratomas, and a
medulloblastoma, and weak or not detectable
to melanomas and carcinomas. Quantitative
absorption with 50 uncultured tumours
generally confirmed this pattern of antigen
expression and demonstrated that neuro-
blastomas and sarcomas can express more
antigen than all adult tissues except brain.
Significant heterogeneity in the quantity of
antigen associated with individual tumours
within these positive classes was observed.
We conclude that Ag390 defines a differen-
tiation antigen that is characteristic ofnormal
neural cells and fibroblasts, and that can be
expressed by neoplastic cells of the same
lineages.
MONOCLONAL ANTIBODIES TO
HUMAN NEUROBLASTOMA CELLS.
J. T. KEMSHEAD & M. F. GREAVES, Membrane
Immunology Laboratory, Imperial Cancer
Research Fund, London, J. PRITCHARD,
Hospital for Sick Children, Great Ormond
Street, London, F. WALSH, Institute of Neur-
ology, Queen Square, London, M. PARKHOUSE
& A. CHAYEN, NationalInst. MedicalResearch,
Mill Hill, London & R. KENNETT, University
ofPennsylvania, Philadelphia, U.S.A.
Neuroblastoma is a malignancy showing no
improvement of prognosis with conventional
low-dose chemotherapy. As an alternative
therapeutic protocol, high-dose drug regimens
are being attempted that require a form of
marrow rescue. For autologous marrow trans-
plantation to be successful it is necessary to
have reagents capable of specifically recog-
nizing and removing metastasizing neuro-
blastoma cells from normal heamopoietic
progenitors in marrow aspirates. To this end
a panel of monoclonal antibodies has been
developed, some of which are neural specific
whilst others cross-react with subsets of
normal haemopoietic cells. Ml/Nl and
P1153/3 react with neuroblastoma cells and
cross-react with cells in the granulocytic and
B-cell lineages respectively. A2B5, UAI,
U13A and D1H7 appear specific for neural
cells, as they do not react with any human
leukaemic cell line or with fresh marrow
aspirate assayed. With these monoclonal
antibodies we have been able to demonstrate
a heterogeneity in antigenic expression in
both human neuroblastoma cell lines and
fresh tumour cells present in heavily infil-
trated marrow aspirates. Analysis of fresh
tumour samples with the panel of antibodies
shows a spectrum of reactivity with some
aspirates showing a lack of reactivity to
certain antibodies. The heterogeneity in anti-
genic expression in neuroblastoma is currently
being investigated, along with the potential
role of the monoclonal antibodies in therapy
(i.e. removal of tumour cells from marrow
prior to re-infusion to patients).
MONOCLONAL ANTIBODIES
AGAINST HUMAN OSTEOGENIC
SARCOMA CELLS. M. J. EMBLETON, B.
GUNN & R. W. BALDWIN, Cancer Research
Campaign Laboratories, University ofNotting-
ham, NG7 2RD, & V. S. BYERS, Dept of
Dermatology, University of California, San
Francisco, California
48 hybridomas were prepared by fusion of
P3-NS1 mouse myeloma cells with spleen
cells from BALB/c mice immunized with cells
of a cultured human osteogenic line, 791T.
2 produced antibody reacting preferentially
with 791T cells by 1251-Protein A binding.
The reactivity ofdifferent clones derived from
the same hybridoma was identical, but there
were differences between the 2 hybridomas.
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Both hybridomas reacted against some
other osteogenic-sarcoma cell lines, but not
against all such lines or identical lines. They
did not react with control fibroblast cultures,
including cells derived from the donors of
791T and cross-reactive sarcomas, or against
erythrocytes or leucocytes from different
donors. However, tests against a panel of
unrelated tumour cell lines revealed a number
of cross reactions, and in this respect the 2
hybridomas showed different specificity. The
antibody binding patterns were thus sugges-
tive of tumour-associated antigens variably
expressed by different tumour cell types.
One ofthe monoclonal antibodies was cyto-
toxic in the presence of rabbit complement,
and experiments are currently in progress to
evaluate its potential in detection or therapy
of tumours growing in immunodeficient
rodents.
IN VIVO IMMUNODETECTION OF
XENOGRAFTED HUMAN TUMOURS
BY MONOCLONAL ANTIBODIES. V.
MOSHAKIS R. J. MCILHINNEY D. RAGHAVAN
& A. M. NEVILLE Ludwig Institutefor Cancer
Research (London Branch), Royal Marsden
Hospital, Sutton, Surrey
A series of human teratoma xenografts have
been established in immunesuppressed mice.
Monoclonal antibodies have been raised to
cell-surface antigens expressed by one of the
teratoma lines (HX39) and used by us to
investigate their potential for in vivo tumour
radiolocalization.
Tumour-bearing mice were injected i.v.
with equal amounts of 1251I-labelled specific
monoclonal antibody (LICR-LON/HT13) and
1311-labelled normal mouse IgG or non-
specific monoclonal IgG simultaneously. At
intervals of up to 4 days after injection, the
animals were killed and radioactivity in
blood, tumours and organs was counted.
It was found that the specific antibody
localized in the tumours between 17 (liver)
and 50 (muscle) times higher than normal
mouse tissues. Tumour/blood ratios reached
in excess of 10, 96 h after injection. Tumour
weight was important, in that the smaller the
tumour, the better the localization. The anti-
teratoma antibody was also shown to localize
in vivo in 4 additional human germ-cell
tumour xenografts but not in non-germ-cell
tumours.
Autoradiography showed that the injected
specific monoclonal antibody was localized to
viable parts of the tumour and in close
association with the tumour-cell surfaces.
Our studies therefore have shown for the
first time, that monoclonal antibodies are
capable of human tumour-xenograft localiza-
tion in vivo. On the basis of these results we
are extending this approach to clinical
studies.
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